Wells Fargo notes that shares of Soleno Therapeutics (SLNO) are down 12% after an update in the FDA FAERS system included a death of a PWS patient receiving VYKAT due to a pulmonary embolism. However, the firm highlights this doesn’t mean VYKAT caused the death and points out that 50% of PWS deaths typically are from cardiac and respiratory issues. The firm, which think this pullback presents a buying opportunity and remains bullish on VYKAT’s launch in PWS, has an Overweight rating and $123 price target on Soleno shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Addresses FDA Adverse Event Report
- Soleno concludes serious adverse reported in FAERS not related to VYKAT XR
- LifeScience Cap’s Optimistic Outlook on Soleno Therapeutics: Vykat XR’s Promising Market Potential and Expansion Plans
- Nu double upgraded, Novavax downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 8/20/2025, According to Top Analysts